XERS Q1 2021 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+358.3% YoY

Gross Profit

$6M77.7% margin

Operating Income

-$17M-204.3% margin

Net Income

-$18M-224.7% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+14.3%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$168M

Total Liabilities

$123M

Stockholders' Equity

$44M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$2M	+358.3%
Gross Profit	$6M	-$2,000	+318550.0%
Operating Income	-$17M	-$28M	+40.8%
Net Income	-$18M	-$29M	+36.9%